Roger Bedimo, M.D., MS, FACP

Reportable Conflicts of Interests:  Research & Educational (CME) Funding: Tibotec Therapeutics, Abbot Pharmaceuticals, Merck & CO, BMS. Advisory Board: Tibotec Therapeutics, Abbott Pharmaceuticals, Merck & CO. 

Disclosure of Financial Conflicts of Interest: None

Education:
Doctor of Medicine
University Center for Health Sciences
University of Yaoundé

Masters of Science in Parasitology
Tulane University Graduate School
New Orleans, LA

Post Graduate or Residency Training:

Infectious Disease Fellowship 2001-2003
University of Alabama at Birmingham
Birmingham, AL

Internal Medicine Residency 1998-2001
Wright State University Medical School
Dayton, OH

Fellowship and Board Certifications:

Board Certification in Infectious Diseases
Board Certification in Internal Medicine
Ohio State Medical License
Alabama State Medical License

Current Position or Practice Site:
Director, Infectious Disease Fellowship Training Program
University of Texas Southwestern Medical Center
Dallas, TX

Adjunct Faculty
Texas/Oklahoma AIDS Education Training Center
Dallas, TX

Associate Professor of Medicine
University of Texas Southwestern
Dallas, TX

Past Positions and/or Appointments:                       
Chief Resident July 2000-December 2000
Wright State University Internal Medicine
Dayton VA Medical Center
Dayton, OH

Professional Memberships:                                       
International AIDS Society-USA
The Infectious Disease Society of America
The American Medical Association
The American College of Physicians
The American Society of Tropical Medicine and Hygiene
The Royal Society of Tropical Medicine and Hygiene

Publications:                                                       
Bedimo, R.  Body-Fat Abnormalities in Patients with HIV: Progress and Challenges.  Journal of the International Association of Physicians in AIDS Care (JIAPAC) (in press).

Hall RG, Payne K, Bain AM, Rahman A, Nguyen S, Eaton SA, and Bedimo R. Multicenter Evaluation of Vancomycin Dosing – Emphasis on Obesity.  Am J Med. 2008 Jun;121(6):515-8.

Bedimo, R. Non-AIDS-defining malignancies among HIV-infected patients in the highly active antiretroviral therapy era. Curr HIV/AIDS Rep. 2008 Aug;5(3):140-9.

Busti AJ, Bain AM, Hall RG 2nd, Bedimo RJ, Leff RD, Meek C, Mehvar R.

Effects of atazanavir/ritonavir or fosamprenavir/ritonavir on the pharmacokinetics of rosuvastatin. J Cardiovasc Pharmacol. 2008 Jun;51(6):605-10.

Busti AJ, Bedimo R, Margolis DM, Hardin DS.  Improvement in insulin sensitivity and dyslipidemia in protease inhibitor-treated adult male patients after switch to atazanavir/ritonavir. J Investig Med. 2008 Feb;56(2):539-44.

Bain AM, Payne KD, Rahman AP, Bedimo R, McClayton D, Rodriguez-Barradas M, and Busti AJ.  The Lipid-Lowering Efficacy of Switching Within Non-Nucleoside Reverse Transcriptase Inhibitors in HIV-Infected Patients. American Journal of Infectious Diseases 2008;4 (2): 147-151.

Rahman AP, Eaton SA, Nguyen, S, Bain AM, Payne K, Bedimo R., and Busti AJ.  The safety and efficacy of simvastatin in treating hyperlipidemia in HIV-infected patients on efavirenz-based HAART. Pharmacotherapy 2008;28(3):323–330.

Nguyen ST, Eaton SA, Bain A, Payne K, Rahman A, Bedimo R, Herrington J, Maclayton D, Rodriguez-Barradas M, Busti AJ.  The lipid lowering efficacy and safety after a switch to an atazanavir/ritonavir based HAART in HIV-infected patients: a multi-center retrospective study.  Pharmacotherapy. 2008 Mar;28(3):323-30.

Chastain LM, Bain AM, Edwards KL, Bedimo R, Busti AJ.  A retrospective study of the lipid lowering efficacy and safety of ezetimibe added to HMG-CoA reductase therapy in HIV-infected patients with hyperlipidemia. Journal of Clinical Lipidology. 2007;1: 634–639.

Morpeth S, Murdoch D, Cabell C, Karchmer A, Pappas P, Levine D, Nacinovich F, Tattevin P, MD⁴; Fernández-Hidalgo N, Dickerman S, Bouza E, del Rio A, Lejko-Zupanc T, de Oliveira A, Iarussi D, Klein J, Chirouze C, Bedimo R, Corey R, Fowler V, and the ICE-PCS Investigators. Non-HACEK* Gram-negative Bacilli Endocarditis: Observations from the International Collaboration on Endocarditis.  Annals of Internal Medicine. 18 December 2007;147(12):829-835.

Cenizal MJ, Skiest D, Luber S, Bedimo R, Davis P, Fox P, Delaney K, Hardy RD. A Prospective Randomized Trial of Empiric Therapy with Trimethoprim-Sulfamethoxazole or Doxycycline for Outpatient Skin and Soft Tissue Infections in an Area of High MRSA Prevalence. Antimicrobial Agents and Chemotherapy 2007 Jul;51(7):2628-30.

Busti AJ, Bedimo R, Margolis D, Hardin D. Improvement in Insulin Sensitivity and Dyslipidemia in Protease Inhibitor-Treated Patients After Switch to Atazanavir/Ritonavir (ATV/RTV): A Prospective Study Using Hyperinsulinemic, Euglycemic Clamp Testing.  Antiv Ther 2006;11:L37.

Kaur R, Bedimo R, Kvanli M, Turner D, Shaw L, and Margolis D. A placebo-controlled pilot study of intensification of antiretroviral therapy with mycophenolate mofetil.  AIDS Research and Therapy 2006 May 26;3(1):16.

Bedimo R, Ghurani R, Nsuami M, Turner D, Kvanli M, Brown G, and Margolis D. Lipid Abnormalities In HIV/HCV Co-Infected Patients.  HIV Medicine, 2006 Nov;7(8):530-6.

Bridges D, Bedimo R. Severe Tuberculosis Sepsis in an Immunocompetent Patient. The American Journal of Medicine. 2006 Mar;119(3):e11-4.

Bedimo R, Chen R, Westfall A, Raper J, Allison J and Saag, M. Sustained HIV Viral Suppression Following Treatment Interruption: An Observational Study.  AIDS Research and Human Retroviruses.  2006 Jan;22(1):40-4.

Bedimo R, Hoesley C, Saag M.  Non-AIDS-Defining Malignancies in the HAART era. Reply to Dal Maso et al. Clin Infect Dis. 2005 Jul 1;41(1):126-127.

Marinella MA, Burdette SD, Bedimo R, Markert RJ. Leukemoid reactions complicating colitis due to Clostridium difficile. South Med J. 2004 Oct;97(10):959-63.

Bedimo R, Chen R, Accort N, et al. Trends in AIDS-Defining and Non-AIDS-Defining Malignancies Among HIV-Infected Patients: 1989 to 2002.  Clin Infect Dis. 2004 Nov 1;39(9):1380-4.

Bahebeck J, Bedimo R, Eyenga V, Kouamfack C, Kingue T, Nierenet M, Sosso M.. The management of musculoskeletal infection in HIV carriers. Acta Orthopædica Belgica. 2004;70(4):355-60.

Bedimo R, Geisler W. Dilantin Hypersensitivity Syndrome Masquerading as Fever and Systemic Illness of Unknown Origin in an HIV-Infected Patient. International Journal of STD & AIDS. 2005 Feb;16(2):178-9.

Bedimo R, Weinstein J. Recurrent extraintestinal Clostridium difficile infection Am J Med 2003;114(9): 770-1.

Bedimo R, Weinstein J. Photo quiz. Disseminated blastomycosis. Clin Infect Dis 2001;33:1706, 1770-1

Cohen DA, Farley TA, Bedimo JR et al. Implementation of a Condom Social Marketing in Louisiana, 1993 to 1996. Am J Public Health. 1999;89:204-208.

Cohen DA, Nsuami M, Bedimo R et al.  A Scool-based Chlamydia Control Program Using DNA Amplification Technology. Pediatrics. 1998;101:1.

Cohen DA, Farley TA, Bedimo R. et al. Cost as a Barrier to Condom Use: the Evidence for Condom Subsidies in the United States. Am J Public Health. 1999;89:567-568.

Books and/or Chapters:
Bedimo R. Non-AIDS-Defining Malignancies among HIV-Infected Patients in the HAART Era Current HIV/AIDS Reports. 2008. In press.

Bedimo R. HIV-Associated Metabolic Complications; International AIDS Society – USA Cases On the Web; http://www.iasusa.org/cow/cow-instructions.php?cowid=72 (last updated 09/2008).

Bedimo R and Skiest D. Fungal Infections of the Central Nervous System.  In Goodkin K, Verma A, Shapshak P (eds.): The Spectrum of Neuro-AIDS Disorders: Pathophysiology, Diagnosis, and Treatment. Washington, DC. American Society for Microbiology (ASM) Press, 2008.

Bedimo R, Margolis M. Challenges of non-AIDS-defining cancers among HIV-infected patients.  Contagion. February 2005 • Vol 2 • No 2.

(Last updated: 2/9/2009)